<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959331</url>
  </required_header>
  <id_info>
    <org_study_id>IJG-SCOUT-2021</org_study_id>
    <nct_id>NCT04959331</nct_id>
  </id_info>
  <brief_title>Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.</brief_title>
  <acronym>SCOUT</acronym>
  <official_title>Clinical Effectiveness and Bacteriological Eradication of Three Different Short-course Antibiotic Regimens and Single-dose Fosfomycin for Uncomplicated Lower Urinary Tract Infections in Adult Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordi Gol i Gurina Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Balearic Islands Health Service (Ibsalut)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria Aragón</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gerencia de Atención Primaria, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jordi Gol i Gurina Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial in which women aged 18 or older and with symptoms of uncomplicated&#xD;
      lower urinary tract infection and a positive urine dipstick analysis will be randomized to&#xD;
      one of the following four groups: 2-day 3 g fosfomycin o.d., 3-day pivmecillinam 400 mg.&#xD;
      t.i.d, 5-day nitrofurantoin 100 mg t.i.d. or a single dose of 3 g of fosfomycin. Sample:&#xD;
      1,000 patients. Two co-primary endpoints are considered: clinical effectiveness at day 7 and&#xD;
      bacteriological eradication at day 14. Follow-up visits are scheduled at days 7 (phone call),&#xD;
      14 and 28 for assessing evolution. Urine samples will be collected in the three on-site&#xD;
      visits and urine cultures performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uncomplicated lower urinary tract infections (LUTI) represent a common problem in primary&#xD;
      care. Resistance of uropathogens to common antibiotics has significantly increased in the&#xD;
      last years. Current local guidelines recommend the use of a single 3 g dose of fosfomycin for&#xD;
      these infections, but most general practitioners prefer short-course therapies to single-dose&#xD;
      therapy. No study has compared head-to-head short course antimicrobial agents for&#xD;
      uncomplicated LUTIs. Therefore, the aim of this randomized clinical trial is to compare three&#xD;
      different short-course antibiotic therapies with single-dose fosfomycin for uncomplicated&#xD;
      LUTIs in adult women. This will be a pragmatic, multicenter, parallel group, open randomized&#xD;
      trial. Women aged 18 or older and with symptoms of uncomplicated LUTI and a positive urine&#xD;
      dipstick analysis will be randomized to one of the following four groups: 2-day 3 g&#xD;
      fosfomycin o.d., 3-day pivmecillinam 400 mg. t.i.d, 5-day nitrofurantoin 100 mg t.i.d. or a&#xD;
      single dose of 3 g of fosfomycin. Sample: 1,000 patients. Two co-primary endpoints are&#xD;
      considered: clinical effectiveness, defined as resolution of symptoms, answered by the&#xD;
      patients at day 7, and bacteriological eradication (proportion of patients bacteriologically&#xD;
      cured) at day 14. Patients will be given a symptom diary for seven days. Follow-up visits are&#xD;
      scheduled at days 7 (phone call), 14 and 28 for assessing evolution. Urine samples will be&#xD;
      collected in the three on-site visits and urine cultures performed. If positive, antibiograms&#xD;
      for the 3 antibiotics studied will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 short-course antibiotic regimens and one-dose of fosfomycin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical effectiveness.</measure>
    <time_frame>Day 7.</time_frame>
    <description>Proportion of patients who report being cured, defined as the resolution of the four symptoms, scoring 0 in the symptom diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacteriological eradication.</measure>
    <time_frame>Day 14.</time_frame>
    <description>Proportion of patients bacteriologically cured, defined as less than 1,000 cfu/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms.</measure>
    <time_frame>From baseline visit to day 7.</time_frame>
    <description>Number of days until the last day the patient scores 0 in any of the four symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological eradication.</measure>
    <time_frame>Day 28.</time_frame>
    <description>Proportion of patients bacteriologically cured, defined as less than 1,000 cfu/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate.</measure>
    <time_frame>Days 7, 14 and 28.</time_frame>
    <description>Proportion of patients presenting a relapse of symptoms within the first four weeks after inclusion in the study and timing of relapse of symptoms and/or bacteriuria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reattendance and complication rate.</measure>
    <time_frame>Days 7, 14 and 28.</time_frame>
    <description>Proportion of patients re-attending healthcare services and development of complications within the first 4 weeks (i.e. pyelonephritis, urosepsis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate.</measure>
    <time_frame>Days 7, 14 and 28.</time_frame>
    <description>Proportion of patients presenting adverse and serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life.</measure>
    <time_frame>Days 0 and 7.</time_frame>
    <description>Change in the quality of life by means of the EQ-5D-5L validated questionnaire (Spanish version).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Short-course fosfomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 g of fosfomycin once daily for two days (sachets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short-course nitrofurantoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Five-day nitrofurantoin 100 mg t.i.d. (pills)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short-course pivmecillinam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three-day pivmecillinam 400 mg. t.i.d. (pills)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-dose fosfomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single 3 g dose of fosfomycin (sachet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin Trometamol Salt</intervention_name>
    <description>Fosfomycin 3 g 2 sachets, taken orally, once daily for two days</description>
    <arm_group_label>Short-course fosfomycin</arm_group_label>
    <other_name>Monurol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin</intervention_name>
    <description>Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days</description>
    <arm_group_label>Short-course nitrofurantoin</arm_group_label>
    <other_name>Furantoin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pivmecillinam</intervention_name>
    <description>Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days</description>
    <arm_group_label>Short-course pivmecillinam</arm_group_label>
    <other_name>Selexid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin Trometamol Salt</intervention_name>
    <description>Fosfomycin 3 g one sachet, taken orally, for one day</description>
    <arm_group_label>Single-dose fosfomycin</arm_group_label>
    <other_name>Monurol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women of 18 years of age or older, with clinical features of uncomplicated&#xD;
        community-acquired lower urinary tract infection including:&#xD;
&#xD;
          -  At least one of four key symptoms of lower urinary tract infection: dysuria, urgency&#xD;
             including nycturia, frequency, and suprapubic tenderness that could be attributed to&#xD;
             an uncomplicated lower urinary tract infection, and no alternative explanation (i.e.&#xD;
             symptoms suggestive of sexually-transmitted infection or vulvovaginitis), and&#xD;
&#xD;
          -  A urine dipstick analysis positive for either nitrites or leukocyte esterase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male sex&#xD;
&#xD;
          -  High suspicion of pyelonephritis (i.e. fever ≥ 37.5°C or flank pain/tenderness)&#xD;
&#xD;
          -  Any condition that may lead or predispose to complicated urinary infection (i.e.&#xD;
             indwelling urinary catheter, pregnancy, immunosuppressive therapy, abnormal urinary&#xD;
             tracts, recurrent urinary tract infection, severe neurological disease affecting the&#xD;
             bladder)&#xD;
&#xD;
          -  Pregnancy or planned pregnancy&#xD;
&#xD;
          -  Symptoms consistent with urinary tract infection in the preceding 4 weeks&#xD;
&#xD;
          -  Patients taking long-term antibiotic prophylaxis&#xD;
&#xD;
          -  Ongoing antibiotic therapy or use of any systemic antibiotic in the previous 7 days&#xD;
&#xD;
          -  Symptoms correlating with differential diagnosis (i.e. vaginal discharge or pain)&#xD;
&#xD;
          -  Hypersensitivity or allergy to β lactams, nitrofurantoin and/or fosfomycin&#xD;
&#xD;
          -  Moderate to severe chronic renal insufficiency&#xD;
&#xD;
          -  Pre-existing polyneuropathy&#xD;
&#xD;
          -  History of lung or liver reaction or peripheral neuropathy after previous use of&#xD;
             nitrofurantoin&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
          -  Porphyria or systemic primary carnitine deficiency or of the type organic aciduria&#xD;
             (i.e. methylmalonic aciduria and propionicacidaemia)&#xD;
&#xD;
          -  Esophageal stricture&#xD;
&#xD;
          -  Current intake of allopurinol or probenecid or valproate&#xD;
&#xD;
          -  Currently part of another randomized clinical trial&#xD;
&#xD;
          -  Previous enrolment in the proposed study&#xD;
&#xD;
          -  Patients living in long-term institutions; and/or&#xD;
&#xD;
          -  Difficulty in conducting scheduled follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Morros, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmacist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Garcia-Sangenís, MD</last_name>
    <phone>0034638687717</phone>
    <email>agarcia@idiapjgol.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramon Monfà, MD</last_name>
    <email>rmonfa@idiapjgol.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arrabal Health Center</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosa Magallón Botaya, MD</last_name>
      <phone>0034976731500</phone>
      <email>med000764@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parque Goya Health Center</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50018</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Cruz Bartolomé Moreno, MD</last_name>
      <phone>+34976765000</phone>
      <email>cruzbrtlm@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Ponça Health Center</name>
      <address>
        <city>Calvià</city>
        <state>Balearic Islands</state>
        <zip>07180</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Ignacio Ramirez Manent, MD</last_name>
      <phone>0034971694345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Escola Graduada Health Center</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Balearic Islands</state>
        <zip>07002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoni Ballester Camps, MD</last_name>
      <phone>0034971717049</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Camp Redó Health Center</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Balearic Islands</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Joan Pou Bordoy, MD</last_name>
      <phone>+34971205551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Son Serra-La Vileta Health Center</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Balearic Islands</state>
        <zip>07013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Catalina Vicens Caldentey, MD</last_name>
      <phone>0034971793193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Gavarra Health Center</name>
      <address>
        <city>Cornellà De Llobregat</city>
        <state>Catalonia</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvia Cobo, MD</last_name>
      <email>scobo@ambitcp.catsalut.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jaume I Health Center</name>
      <address>
        <city>Tarragona</city>
        <state>Catalonia</state>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana Moragas, MD PhD</last_name>
      <phone>0034600072170</phone>
      <email>anamaria.moragas@urv.cat</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Hernandez, MD PhD</last_name>
      <phone>607811649</phone>
      <email>silviaha@comt.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Valleaguado Health Center</name>
      <address>
        <city>Coslada</city>
        <state>Madrid</state>
        <zip>28823</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Lidia Escribano González, MD</last_name>
      <phone>0034916690024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Fernando Health Center</name>
      <address>
        <city>San Fernando De Henares</city>
        <state>Madrid</state>
        <zip>28830</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Benito Ortiz, MD</last_name>
      <phone>0034916691266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Villarejo de Salvanés Health Center</name>
      <address>
        <city>Villarejo de Salvanés</city>
        <state>Madrid</state>
        <zip>28590</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jaime Marín Cañada, MD</last_name>
      <phone>0034918745017</phone>
      <email>jmarin29@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Los Alpes Health Center</name>
      <address>
        <city>Madrid</city>
        <zip>28022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Victoria Garcia Espinosa, MD</last_name>
      <phone>0034917759109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aquitania Health Center</name>
      <address>
        <city>Madrid</city>
        <zip>28032</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Marta Lor Leandro, MD</last_name>
      <phone>0034913135323</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.idiapjgol.org/index.php/en/</url>
    <description>The protocol of the study will be available on this webpage</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Tract Infections</keyword>
  <keyword>Women</keyword>
  <keyword>Patient Outcome Assessment</keyword>
  <keyword>Bacteriological Eradication</keyword>
  <keyword>Urinalysis</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Antimicrobial Resistance</keyword>
  <keyword>Short Course</keyword>
  <keyword>Primary Health Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
    <mesh_term>Amdinocillin Pivoxil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>On request after publication.</ipd_time_frame>
    <ipd_access_criteria>Principal investigator's email (carles.llor@gmail.com)</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

